APA (7th ed.) Citation

Bukhari, M., Mann, O., & Sultan, Z. (2024). POS1150 PERFORMANCE OF FRAX™ RISK FACTORS IN PREDICTING FRACTURE RISK IN A COHORT OF PATIENTS TREATED WITH AROMATASE INHIBITORS FOR BREAST CANCER. Annals of the rheumatic diseases, 83(Suppl 1), 1121-1122. https://doi.org/10.1136/annrheumdis-2024-eular.5981

Chicago Style (17th ed.) Citation

Bukhari, M., O. Mann, and Z. Sultan. "POS1150 PERFORMANCE OF FRAX™ RISK FACTORS IN PREDICTING FRACTURE RISK IN A COHORT OF PATIENTS TREATED WITH AROMATASE INHIBITORS FOR BREAST CANCER." Annals of the Rheumatic Diseases 83, no. Suppl 1 (2024): 1121-1122. https://doi.org/10.1136/annrheumdis-2024-eular.5981.

MLA (9th ed.) Citation

Bukhari, M., et al. "POS1150 PERFORMANCE OF FRAX™ RISK FACTORS IN PREDICTING FRACTURE RISK IN A COHORT OF PATIENTS TREATED WITH AROMATASE INHIBITORS FOR BREAST CANCER." Annals of the Rheumatic Diseases, vol. 83, no. Suppl 1, 2024, pp. 1121-1122, https://doi.org/10.1136/annrheumdis-2024-eular.5981.